S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ARGX

argenx (ARGX) Stock Price, News & Analysis

$393.72
-4.87 (-1.22%)
(As of 03/28/2024 ET)
Today's Range
$391.70
$397.79
50-Day Range
$356.95
$411.20
52-Week Range
$327.73
$550.76
Volume
184,653 shs
Average Volume
349,755 shs
Market Capitalization
$23.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$530.74

argenx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
34.8% Upside
$530.74 Price Target
Short Interest
Healthy
2.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of argenx in the last 14 days
Based on 28 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.07) to $3.53 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.29 out of 5 stars

Medical Sector

357th out of 938 stocks

Biological Products, Except Diagnostic Industry

50th out of 152 stocks

ARGX stock logo

About argenx Stock (NASDAQ:ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Stock Price History

ARGX Stock News Headlines

argenx (NASDAQ:ARGX) Given Buy Rating at HC Wainwright
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Key Takeaways From argenx Analyst Ratings
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Reasons to Invest in argenx (ARGX)
argenx NV ADR (ARGX)
argenx SE (ARGX) Q4 2023 Earnings Call Transcript
Argenx price target raised by $56 at Scotiabank, here's why
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
843
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$530.74
High Stock Price Target
$641.00
Low Stock Price Target
$408.00
Potential Upside/Downside
+34.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
21 Analysts

Profitability

Net Income
$-295,050,000.00
Pretax Margin
-24.00%

Debt

Sales & Book Value

Annual Sales
$1.27 billion
Book Value
$69.22 per share

Miscellaneous

Free Float
57,861,000
Market Cap
$23.39 billion
Optionable
Optionable
Beta
0.65
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Timothy Van Hauwermeiren EMBA (Age 52)
    M.B.A., M.Sc., CEO & Executive Director
    Comp: $1.44M
  • Mr. Karl Gubitz (Age 54)
    Chief Financial Officer
  • Ms. Malini Moorthy (Age 54)
    General Counsel
  • Mr. Arjen Lemmen M.Sc. (Age 39)
    Vice President of Corporate Development & Strategy
  • Ms. Andria Wilk (Age 50)
    Global Head of Quality
  • Mr. Luc Truyen (Age 59)
    Chief Medical Officer
  • Ms. Karen Massey (Age 45)
    Chief Operating Officer
  • Mr. Filip Borgions
    VP & Global Head of Technical Operations
  • Mr. Peter Ulrichts (Age 44)
    Chief Scientific Officer
  • Ms. Beth DelGiacco
    VP and Global Head of Corporate Communications & Investor Relations

Should I Buy argenx Stock? ARGX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in argenx SE:

  • argenx stock price has shown resilience, currently trading at a level that presents a potential buying opportunity.
  • Positive analyst ratings and target price adjustments from reputable firms like Raymond James and Wells Fargo & Company indicate confidence in the company's future performance.
  • Recent growth in institutional investments, such as Schonfeld Strategic Advisors LLC increasing its stake by 421.6%, can signal strong market sentiment towards argenx.
  • argenx's revenue of $417.84 million for the last quarter exceeded analysts' expectations, showcasing the company's revenue-generating capabilities.
  • argenx's 52-week high of $550.76 suggests potential for capital appreciation if the stock returns to previous highs.

Cons

Investors should be bearish about investing in argenx SE for these reasons:

  • argenx reported a negative return on equity of 30.97% and a negative net margin of 23.26%, indicating financial challenges that may impact investor returns.
  • Deutsche Bank AG significantly reduced its holdings in argenx by 95.5% in the third quarter, which could raise concerns about the company's future performance.
  • Evercore ISI lowered its target price on argenx, signaling potential risks or challenges ahead for the company.
  • argenx's 12-month low of $327.73 may indicate volatility in the stock price, posing risks for short-term investors.
  • The company's PE ratio of -98.44 suggests that argenx is currently not profitable, which could deter some investors seeking immediate returns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 25, 2024. Please send any questions or comments about these argenx pros and cons to contact@marketbeat.com.

ARGX Stock Analysis - Frequently Asked Questions

Should I buy or sell argenx stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 sell rating, 5 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price target for 2024?

21 analysts have issued twelve-month price objectives for argenx's stock. Their ARGX share price targets range from $408.00 to $641.00. On average, they expect the company's stock price to reach $530.74 in the next year. This suggests a possible upside of 34.8% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2024?

argenx's stock was trading at $380.43 at the beginning of 2024. Since then, ARGX shares have increased by 3.5% and is now trading at $393.72.
View the best growth stocks for 2024 here
.

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ARGX earnings forecast
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its quarterly earnings results on Thursday, February, 29th. The company reported ($1.68) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by $0.45. The firm had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. argenx had a negative trailing twelve-month return on equity of 16.97% and a negative net margin of 23.26%. During the same period in the prior year, the company posted ($0.70) earnings per share.

What guidance has argenx issued on next quarter's earnings?

argenx issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $374.0 million-$374.0 million, compared to the consensus revenue estimate of $358.9 million.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

argenx (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

argenx's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.21%), Artisan Partners Limited Partnership (5.36%), Capital World Investors (3.31%), Avoro Capital Advisors LLC (2.09%), Bellevue Group AG (1.47%) and RTW Investments LP (1.13%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARGX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners